Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Emergent BioSolutions Inc EBS

Healthcare Biotechnology
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.


NYSE:EBS - Post by User

Emergent BioSolutions Inc
<< Previous
 Bullboard Posts
User Avatar Image
(86)
•••
Post by whytestockson Feb 21, 2024 10:30am
40 Views
Post# 35890809

Emergent BioSolutions Appoints New President and CEO

Emergent BioSolutions Appoints New President and CEO
NEWS: $EBS Emergent BioSolutions Appoints New President and CEO2024-02-21 08:04:03 ET DENVER, Colo., Feb 21, 2024 (www.247marketnews.com)- Emergent BioSolutions Inc. (NYSE: EBS ) reported, this morning, that Joseph C. Papa was appointed president and CEO, effective today. EBS is trading at $1.71, up $0.19 (+12.50%), on 46K shares traded. It...EBS - Emergent BioSolutions Appoints New President and CEO

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities